Capricor Therapeutics (CAPR) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts CAPR Hot Sheet
Join SI Premium – FREE
Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.35), $0.01 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $3.97 million versus the consensus estimate of $4.41 million.
For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- Encompass Health Corporation (EHC) files mixed shelf
- Constellation Brands pledges $100M to U.S. farmers over five years
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
